# Cellix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cellix

- Industry: Medical Devices & Equipment
- Headquarters: Dublin, Ireland
- Website: www.cellixltd.com
- Total disclosed funding: $2.7M
- Latest round: Series B (Jul 11, 2008)
- Investors on record: 3

## About

Cellix Ltd. is a Dublin-based company specializing in the development of microfluidic technologies, including pumps and biochips for life science research applications.Cellix Ltd. focuses on the design and manufacturing of microfluidic devices, particularly for droplet generation and organ-on-chip studies. The company was co-founded by Dmitry Kashanin and Igor Shvets, with Vivienne Williams currently serving as CEO. Cellix has its headquarters in Dublin, Ireland, and has successfully closed a total of 3 funding deals, with the most recent investment occurring in September 2009, raising EUR 500 thousand from APICAP and Enterprise Ireland. This funding round valued the company at EUR 4.447 million post-money.Cellix Ltd. specializes in microfluidic technologies, focusing on microfluidic pumps and biochips for droplet generation and organ-on-chip studies. Their flagship products, such as the Inish Analyser and VenaFlux microfluidic pumps, enable precise fluid flow control, essential for research in thrombosis and inflammation. Their products cater to academic institutions, biotechnology companies, and pharmaceutical firms, with clients including University College London and Lawrence Berkeley National Laboratory. Cellix markets its products globally across Europe, North America, and Asia.Cellix Ltd. generates revenue through the direct sales of microfluidic products and solutions, primarily utilizing a B2B model. Their revenue comes from equipment sales such as the Inish Analyser and VenaFlux microfluidic pumps, often accompanied by subscription services for technical support and software updates. The pricing structure reflects the specialized nature of their offerings, which may involve tailored configurations and service agreements to meet specific research demands, supporting their commitment to enhancing life science research efficiency.Cellix Ltd. aims to enhance its product line with new microfluidic technologies and upcoming releases, though specific details on these products remain undisclosed. The company is also strategically planning to expand into new geographic markets; however, specific regions targeted for this expansion have not been detailed. The recent funding round of EUR 500 thousand raised in September 2009 will be utilized to support these growth initiatives, further enhancing their capabilities and market reach.

## Funding rounds

- Series B, Jul 11, 2008, $1.7M — Investec Ventures, APICAP
- Seed, Dec 22, 2006, $1M — Investec Ventures, Enterprise Ireland, APICAP

## Investors

- Investec Ventures (https://capitalatlas.ai/funds/investec-ventures) — Seed, Series B
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Seed
- APICAP (https://capitalatlas.ai/funds/apicap) — Seed, Series B